Document is current
Any future updates will be listed below
-
Authors
Johannessen, Tonje R.
Halvorsen, Sigrun
Atar, Dan
Munkhaugen, John
Nore, Anne Kathrine
Wisløff, Torbjørn
Vallersnes, Odd Martin
-
Funding
Funding for this research was provided by:
Norwegian Research Fund for General Practice
Norwegian Committee on Research in General Practice
Norwegian Medical Association's Fund for Quality Improvement and Patient Safety
- License Information
-
More Information
Article History
Received: 4 January 2022
Accepted: 18 October 2022
First Online: 21 October 2022
Declarations
:
: The OUT-ACS study was performed in accordance with the Declaration of Helsinki and approved by the <i>Regional Committee for Medical and Health Research Ethics Northern Norway (REC North; ref. 2016/1241)</i> and the <i>Oslo University Hospital Information Security and Privacy Office (no. 2016/13308)</i>. Written informed consent was obtained from all subjects in the OUT-ACS cohort. For the hospital cohort, written informed consent was not required for the anonymous administrative information extracted from Drammen Hospital (<i>The Health Research Act §20,</i>). The OUT-ACS study was registered at <i>ClinicalTrial.gov (NCT02983123)</i> and was carried out according to relevant regulations and guidelines. For this current cost-effectiveness analysis, the <i>Consolidated Health Economic Evaluation Reporting Standards (CHEERS)</i> statement was followed.(50).
: Not applicable.
: DA has received speaker and consultancy honoraria from Roche Diagnostics and Siemens Healthcare. Outside the submitted work, JM received modest lecture fees from Sanofi, Amgen, and Bayer. The remaining authors have no conflicts to declare.
